Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219310 · ClinicalTrials.gov registry record · Phase 4
RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00219310: Completed Phase 4 study, sponsored by Novartis.
NCT00219310 is a Phase 4 study that has completed, run by Novartis. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00219310, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
This trial will assess whether RGH patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their RGH.
Interventions
- DRUG Famciclovir
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-06 |
| Est. Completion | 2005-06 |
| Phase | Phase 4 |
What the finished NCT00219310 record still lists
NCT00219310 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Famciclovir is the first listed.
NCT00219310 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00219310 about?
NCT00219310 is a clinical study titled "RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir". This trial will assess whether RGH patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their RGH.
What is the current status of trial NCT00219310?
This trial is currently completed. It is a Phase 4 study. The study started on 2003-06. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00219310?
The interventions under investigation include: Famciclovir (DRUG).
Who is sponsoring clinical trial NCT00219310?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia